(Q54376091)

English

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.

scientific article published on 26 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. (English)

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

1 reference

based on heuristic

inferred from title

Irene L Andrulis

8

object named as

I L Andrulis

1 reference

Europe PubMed Central

29 May 2018

author name string

F P O'Malley

1

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

S Chia

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

D Tu

3

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

L E Shepherd

4

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

M N Levine

5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

D Huntsman

6

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

V H Bramwell

7

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

K I Pritchard

9

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

language of work or name

0 references

publication date

26 April 2011

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

128

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

2

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

401-409

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

https://scigraph.springernature.com/pub.10.1007/s10549-011-1511-5

0 references

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

HER2/neu in systemic therapy for women with breast cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Gr

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Role of proliferation in HER2 status predicted response to doxorubicin.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Topoisomerase IIalpha and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1511-5

21 January 2018

Identifiers

10.1007/S10549-011-1511-5

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

release_arjj5s55gng3halwtny6dys5wu

1 reference

https://api.fatcat.wiki/v0/release/arjj5s55gng3halwtny6dys5wu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

29 May 2018

http://europepmc.org/abstract/MED/21519837

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54376091&oldid=1837183874"